Medtronic stock gets FDA label update after renal denervation data
Published on 11/10/2026 at 12:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSClinical evidence supports cardiovascular portfolio
- SPYRAL AFFIRM reported significant six-month blood-pressure reductions across office, home and 24-hour measurements.
- The FDA-approved label update adds clinical evidence for isolated systolic hypertension, chronic kidney disease up to stage 3b and type 2 diabetes.
- Medtronic's fiscal second-quarter results are scheduled for November 24.
Medtronic announced on November 3 that its Symplicity Spyral renal denervation system met the primary endpoint in the SPYRAL AFFIRM post-approval study. The company's November 3 release said the six-month results showed statistically significant blood-pressure reductions in patients with uncontrolled hypertension.
Renal denervation evidence broadens
Office systolic blood pressure fell 18.2 mmHg from baseline, while home blood pressure declined 9.4 mmHg and 24-hour ambulatory pressure decreased 9.7 mmHg. Medtronic said antihypertensive medication use was unchanged through six months, at an average of 3.6 medications per patient.
The composite safety endpoint occurred in 2.1% of patients, and nearly nine out of 10 participants experienced a clinical benefit at six months. The study was prospective, multicenter and single-arm, and included diverse patient groups such as women, Black and Hispanic patients, and people aged 65 and older.
The US Food and Drug Administration also approved an update to the Symplicity Spyral catheter labeling. The revised label adds clinical evidence for patients with isolated systolic hypertension, chronic kidney disease up to stage 3b and type 2 diabetes. The indication for use remains unchanged, so the update expands the evidence available to physicians rather than changing the authorized treatment indication.
What investors watch next
Medtronic stock traded at 92.41 euros on Lang & Schwarz at 12:00:01 CET on Tuesday, November 10. The renal denervation data give the cardiovascular portfolio an additional clinical support point, but the next financial test is whether adoption and procedure volumes become visible in reported segment performance.
Medtronic is scheduled to report fiscal second-quarter results on November 24. Investors can use that update to assess whether the Symplicity Spyral evidence is translating into commercial momentum and whether management provides further detail on the product's role in cardiovascular growth.
For broader market context, see the S&P 500.
More news and analyses on Medtronic stock.
Medtronic plc
- Company: Medtronic plc
- ISIN: IE00BTN1Y115
- Quote: 92.41 euros on Lang & Schwarz, November 10, 2026, 12:00:01 CET
